1361. Pharmacokinetics and Safety of Ridinilazole (RDZ) a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients

摘要

BackgroundCDI is the leading cause of nosocomial diarrhea associated with 29,000 deaths p.a. in the United States. RDZ is a novel oral drug highly selective for C. difficile limiting collateral damage to the gut microbiota. Here we present a combined analysis of all pharmacokinetic (PK) and tolerability data obtained throughout the development of RDZ from animal models to Phase 2, including new human PK data.